A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2018
Price : $35 *
At a glance
- Drugs Velusetrag (Primary)
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Proof of concept; Therapeutic Use
- Sponsors Theravance
- 18 May 2015 Results published in a Theravance Biopharma media release.
- 18 May 2015 According to a Theravance Biopharma media release, data from this study were presented at the Digestive Disease Week (DDW) 2015.
- 31 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.